productively replicate in vivo, such as HBV, HCV, H. pylori, and the parasites, cause tissue inflammation, leading to the accumulation of damage in host cells. [3] [4] [5] [6] [7] In contrast, EBV, KSHV, HPV, and HTLV-1 establish latent infection, and most individuals infected with these viruses are asymptomatic. [8] [9] [10] [11] Each of these latent viruses encodes its own oncogene(s); however, these oncogenes are tightly regulated and selectively expressed in cancer cells in vivo. Finally, HIV is unique among the pathogens categorized in IARC's Group 1, as it doesn't have oncogenic potential itself, but it increases cancer risk by allowing other oncogenic agents to propagate in coinfected subjects. 1, 12 Collectively, infectious agents are thought to cause cancer by one or more of the following mechanisms: persistent inflammation, potent oncogenic activity, and promoting escape from host immunity. The first mechanism (inflammation) is reviewed elsewhere. 13, 14 We will begin this discussion by focusing on the second mechanism (oncogenic factors produced by pathogens), and then we will discuss how various pathogens (including HIV) can interact with one another to further increase the risk of cancer.
| COLLABORATION OF VIR AL FACTOR S ALLOWS PROLIFER ATION OF INFECTED CELLS WITH D NA DAMAGE: POSSIBLE MECHANISM OF MALIGNANT TRANSFOR MATION
Viral oncogenes play important roles in the persistent proliferation and survival of infected cells, resulting in malignant transformation. It is known that the potent activity of any of several viral oncoproteins would normally induce the cellular DDR, leading to apoptosis or OIS.
Subversion of the OIS pathway 15 by the collaboration of two or more viral factors is a common mechanism that drives the increase in infected cells with genetic abnormalities.
| HTLV-1 Tax and HBZ
Human T-cell leukemia virus type 1 is a retrovirus that induces a malignant disease of CD4+ T cells, ATL. 16 The HTLV-1 provirus is integrated into the host genome and encodes several regulatory and accessory Tax is a highly immunogenic protein, and therefore it is a main target of CTL. [33] [34] [35] on the surface of T cells, and suppresses the immune response through induction of IL-10 from dendritic cells. 39 In addition, vaccination with Tax protein is less efficient in HBZ-transgenic mice than in wild-type littermates. 39 These results suggest that HBZ expressed in infected cells can suppress anti-Tax immunity in vivo. Anti-HBZ CTL are less frequent than anti-Tax CTL in HTLV-1-infected subjects despite the constant expression of HBZ, implying that the immunogenicity of HBZ is low. 40 In addition, HBZ suppresses the intracellular inhibitory signal through TIGIT by inactivation of SHP-2 and, consequently, enhances cell proliferation upon TCR stimulation. 41 Taken together, these reports indicate that Tax stimulates many oncogenic pathways while HBZ counterbalances the negative effects of Tax, leading to malignant transformation of infected cells.
| HPV E6 and E7
High . 42 The transforming activity of E7 is strongly increased in the presence of E6. E7 triggers a carcinogenic cascade by binding to pRb and inactivating it; the resulting activation of E2F transcription factors promotes cell proliferation. Overactive E2Fs would normally cause p53 activation and induce apoptosis or senescence as a cellular defense response; however, the E6/E6-associated protein (E6AP) complex ubiquitinates p53 for proteasomal degradation. Thus, the sequential effects of E7 and E6 trigger oncogenesis in HPV-infected cells. It has also been reported that high-risk, but not low-risk, HPV E7 causes p16 INK4A induction in a pRb-independent way -a phenomenon that is also observed in Ras-mediated OIS. 43, 44 A recent genomic sequencing study showed that the sequence of HPV16 E7
is strictly conserved in precancerous and cancerous tissues, suggesting its importance in carcinogenesis. 45 Collectively, these studies show that persistent replicative stresses from E7 and inhibition of cell cycle arrest and senescence by E6 induce the accumulation of genetic aberrations and, consequently, increase the probability of malignant transformation by HPV. It is also known that HPV E5 protein has oncogenic properties; it promotes cell proliferation by stimulation of EGFR, and suppresses TRAIL-and FasLmediated apoptosis. 46, 47 In addition, E5 downregulates expression of MHC class I, class II, and CD1d on the surface of infected cells, enabling them to escape from CTL and NKT cells. 46 Thus, E5 plays important collaborative roles in HPV-mediated carcinogenesis, especially by modulation of host immune systems.
| EBV oncoproteins
Human herpesviruses including EBV and KSHV establish latent infection in the host by expressing a limited number of gene products. 48 This latency is reversible -the virus can resume productive viral 
| KSHV v-cyclin and vFLIP
Kaposi's sarcoma-associated herpesvirus v-cyclin and vFLIP are encoded in the same viral mRNA and expressed in latently infected cells. 48 v-cyclin accelerates cell cycle progression, triggers the DDR, and finally induces autophagy and senescence in primary human foreskin fibroblasts ( Figure 2D ). In contrast, a potent viral anti-apoptotic factor, vFLIP, suppresses v-cyclin-induced senescence, contributing to the expansion of KSHV-infected cells with DNA damage. 55 vFLIP also induces G1 arrest/senescence in HeLa cells through hyperactivation of NF-jB that is reminiscent of Taxmediated senescence. In this setting, v-cyclin prevents cell cycle arrest by vFLIP. 56 It is suggested that these two proteins work in concert to accelerate the transformation of KSHV-infected cells.
In summary, investigations of a variety of oncogenic viruses have
shown a common scheme: viral gene products collaborate to induce proliferation while blocking senescence.
| ENH ANCEME NT OF CANCER DEVELOPMENT BY COINFECTION WITH MULTIPLE AGENTS
Collaboration of viral gene products in oncogenesis is not limited to gene products that all come from the same virus. In some cases, coinfection with two or more pathogens is associated with a higher cancer risk than infection with either of the pathogens alone. Recent studies have shown a variety of molecular mechanisms for this enhanced oncogenesis. Here, we summarize several examples.
| Strongyloidiasis and infective dermatitis as risk factors for ATL
Two types of superinfections are associated with an increased risk of ATL in people already infected with HTLV-1. The first, strongy-
loidiasis, is a chronic parasitic infection of humans caused by
Strongyloides stercoralis. HTLV-1 proviral load is higher in S. stercoralis-positive carriers than in non-coinfected subjects, 57 and the incidence of ATL is high in such superinfected subjects, 58 suggesting that S. stercoralis facilitates the clonal proliferation of HTLV-1-infected cells. The second type of superinfection associated with increased ATL risk is IDH: a refractory skin infection with Staphylococcus aureus and/or beta-hemolytic Streptococci observed in HTLV-1-infected children in developing countries. 59 In IDH patients, HTLV-1 proviral load is also higher 60 and clonal expansion occurs at a higher rate than in subjects infected with HTLV-1 only. 61 A recent study showed that clonal expansion and turnover of HTLV-1-infected cells are increased in patients coinfected with S. stercoralis. 61 These observations suggest that coinfection with S. stercoralis 
| HIV-associated cancers
Human immunodeficiency virus 1 is rated a Group 1 oncogenic agent by the IARC. people. 64 The rate of EBV-positive HL is higher in HIV-1 infected cases than in the general population, 65 suggesting that EBV is closely involved in the genesis of HIV-mediated HL. Importantly, the standard incidence rate of HL in HIV-infected subjects has increased despite entering the era of combination antiretroviral therapy, whereas that of NHL has dropped. 66 These findings suggest that there are distinct mechanisms of lymphomagenesis by EBV in the presence of immune modulation by HIV, and that these mechanisms vary between HL and NHL. KSHV 67 and Merkel cell polyomavirus (MCPyV) 68 were first identified from cancer cells of AIDS-related Kaposi's sarcoma and Merkel-cell carcinoma respectively, and are now recognized as causative agents of each cancer. KSHV is also associated with a rare subtype of B-cell lymphoma, primary effusion lymphoma (PEL), which occurs predominantly in the pleural or peritoneal cavity. The risk of HPV-associated cancers, such as cervical cancer, anal cancer, and oropharyngeal cancer, is also elevated among persons with AIDS. HIV-1 is also associated with several cancers that have not been linked to other oncogenic pathogens. The risk of lung cancer is higher in HIV-infected subjects than in the general population, and the higher smoking rate in the HIV-infected population is one of the factors explaining this trend. 71 In addition, recent studies show that immunosuppression by HIV and chronic inflammation are involved in oncogenesis. 72 It is known that HIV infection is a risk factor for cancers of the conjunctiva and the lip. 12 Impairment of anti-cancer immunity by HIV is a possible mechanism for the emergence of these malignancies.
| EBV and malaria
Burkitt lymphoma (BL) is an aggressive B-cell malignancy originating from a GC, and it can be classified into three subtypes according to clinical features: endemic BL, sporadic BL, and HIV-associated BL. 73 eBL is the most common childhood cancer in Africa, and more than 95% of cases are associated with EBV. In addition, it occurs at higher incidence in areas in which malaria is endemic; therefore an additional role of malaria in the etiology has long been suspected. 74 Malaria is caused by several species of Plasmodium. A recent study demonstrated that chronic infection with Plasmodium in mice promotes clonal expansion of GC cells and induces expression of AID, which is associated with genetic mutations and chromosomal translocations. 75 It is suggested that Plasmodium superinfection promotes EBV-mediated oncogenesis by inducing genomic aberrations, leading to the distinct B-cell malignancy, eBL.
| Helicobacter pylori and EBV
Most gastric cancers are associated with infection of gastric epithelial cells with H. pylori. 12 Helicobacter pylori is a highly heterogeneous bacterium with a large genomic diversity. Helicobacter pylori strains possessing the cagA gene are more virulent than cagA-negative strains, and the CagA protein is closely linked to severe diseases such as peptic ulcers and gastric cancer. 76 EBV is also causally associated with gastric carcinoma, and approximately 10% of cases contain EBV in tumor cells. 53 Recently, the mechanism of cooperative oncogenesis by these two pathogens was clarified. 77 CagA is hypermethylation in the SHP1 promoter region. Thus, EBV cancels the negative effect of SHP1 on gastric carcinogenesis by H. pylori.
This may be a distinct mechanism of gastric cancer induced by dual agents.
| Schistosoma haematobium and bacterial infection
Schistosoma haematobium is endemic in sub-Saharan Africa and the Middle East, and induces urinary bladder cancer. 7, 78 Bacterial superinfection is suggested to be a risk factor for S. haematobium-associated bladder cancer. Schistosoma haematobium migrate into the bladder tissue and cause chronic granulomatous inflammation in the mucosal and submucosal layers of the bladder. The inflammation leads to the development of squamous metaplasia and urine stasis, resulting in bacterial infection. Some of the bacteria are thought to be associated with the endogenous formation of carcinogenic N-nitrosamines in the urinary tract. It is suggested that coinfection with S. haematobium and these bacteria thus initiates oncogenic processes in the bladder.
| CON CLUDING REMARKS
In the present review, we summarized the mechanisms by which mul- 
